| Literature DB >> 20563663 |
Ruben Schouten1, Dorothee C Wiryasaputra, Francois M H van Dielen, Wim G van Gemert, Jan Willem M Greve.
Abstract
Laparoscopic adjustable gastric banding (LAGB) and vertical-banded gastroplasty (VBG) are surgical treatment modalities for morbid obesity. This prospective study describes the long-term results of LAGB and VBG. One hundred patients were included in the study. Fifty patients underwent LAGB and 50 patients, open VBG. Study parameters were weight loss, changes in obesity-related comorbidities, long-term complications, re-operations including conversions to other bariatric procedures and laboratory parameters including vitamin status. From 91 patients (91%), data were obtained with a mean follow-up duration of 84 months (7 years). Weight loss [percent excess weight loss (EWL)] was significantly more after VBG compared with LAGB, 66% versus 54%, respectively. All comorbidities significantly decreased in both groups. Long-term complications after VBG were mainly staple line disruption (54%) and incisional hernia (27%). After LAGB, the most frequent complications were pouch dilatation (21%) and anterior slippage (17%). Major re-operations after VBG were performed in 60% of patients. All re-operations following were conversions to Roux-en-Y gastric bypass (RYGB). In the LAGB group, 33% of patients had a refixation or replacement of the band, and 11% underwent conversion to another bariatric procedure. There were no significant differences in weight loss between patients with or without re-interventions. No vitamin deficiencies were present after 7 years, although supplement usage was inconsistent. This long-term follow-up study confirms the high occurrence of late complications after restrictive bariatric surgery. The failure rate of 65% after VBG is too high, and this procedure is not performed anymore in our institution. The re-operation rate after LAGB is decreasing as a result of new techniques and materials. Results of the re-operations are good with sustained weight loss and reduction in comorbidities. However, in order to achieve these results, a durable and complete follow-up after restrictive procedures is imperative.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20563663 PMCID: PMC2996534 DOI: 10.1007/s11695-010-0211-2
Source DB: PubMed Journal: Obes Surg ISSN: 0960-8923 Impact factor: 4.129
Preoperative patient characteristics
| LAGB | VBG |
| |
|---|---|---|---|
| Patients ( | 50 | 50 | – |
| M/F ( | 10:40 | 10:40 | – |
| Age (years) | 39 ± 8 | 37 ± 9 | 0.32 |
| Weight (kg) | 133 ± 21 | 131 ± 24 | 0.87 |
| BMI (kg/m²) | 47 ± 6 | 47 ± 6 | 0.97 |
| Total comorbidities ( | 1.3 ± 1.0 | 1.3 ± 1.1 | 0.97 |
a t test
Long-term complications
| LAGB | VBG “non-converted” | RYGB “converted VBG” | |
|---|---|---|---|
| ( | ( | ( | |
| Reflux | 3 (6%) | 1 (6%) | 0 (0%) |
| Vomiting | 20 (42%) | 7 (41%) | 0 (0%) |
| Dysphagia | 1 (2%) | 1 (6%) | 1 (4%) |
| Port-related problems | 5 (10%) | – | – |
| Re-operations | 16 (33%) | 11 (26%) | 2 (8%) |
| Conversions | 5 (10%) | 26 (65%) | – |
| Second re-operation | 1 (5%) | 2 (8%) | – |
Fig. 1Flow chart of follow-up, re-operations, and conversions
Weight loss after 2 and 7 years
| LAGB ( | VBG “non-converted” ( | RYGB “converted VBG” ( | |
|---|---|---|---|
| BMI (preoperative) | 47 ± 6 ( | 43 ± 7 ( | 48 ± 6 ( |
| BMI (2 years) | 34 ± 6 ( | 30 ± 5 ( | 33 ± 7 ( |
| EWL (2 years) | 55% ± 22 ( | 73% ± 23 ( | 66% ± 27 ( |
| BMI (7 years) | 35 ± 7 ( | 31 ± 6 ( | 31 ± 5 ( |
| EWL (7 years) | 54% ± 25 ( | 69% ± 22 ( | 69% ± 24 ( |
aConverted LAGB patients (n = 5) were excluded
Obesity-related comorbidities 2 and 7 years postoperatively (LAGB and VBG patients)
| LAGB | VBG | |||||
|---|---|---|---|---|---|---|
| Preop ( | 2 years ( | 7 years ( | Preop ( | 2 years ( | 7 years ( | |
| Diabetes | 5 | 1 | 5 | 7 | 1 | 0 |
| Hypertension | 7 | 3 | 4 | 10 | 1 | 6 |
| Joint problems | 28 | 11 | 17 | 29 | 12 | 17 |
| Hyperchol. | 2 | 1 | 0 | 2 | 1 | 1 |
| OSAS | 1 | 0 | 0 | 1 | 0 | 0 |
Obesity-related comorbidities 2 and 7 years postoperatively (VBG and converted VBG to RYGB patients)
| VBG “non-converted” ( | RYGB “converted VBG” ( | ||||
|---|---|---|---|---|---|
| Preop ( | 2 years ( | 7 years ( | 2 years ( | 7 years ( | |
| Diabetes | 7 | 1 | 0 | 0 | 0 |
| Hypertension | 10 | 1 | 3 | 0 | 3 |
| Joint problems | 29 | 6 | 8 | 6 | 9 |
| Hyperchol. | 2 | 0 | 0 | 1 | 1 |
| OSAS | 1 | 0 | 0 | 0 | 0 |
Laboratory measurements: LAGB versus VBG/GB
| LAGB ( | VBG ( | Normal range |
| |
|---|---|---|---|---|
| Hemoglobin | 8.1 | 7.9 | 7.5–10.0 (mmol/L) | 0.61 |
| ASATb | 17 | 20 | <35 (U/L) | 0.13 |
| ALATc | 21 | 23 | <40 (U/L) | 0.58 |
| Albumin | 39 | 39 | 35–50 (g/L) | 0.94 |
| Total protein | 69 | 67 | 60–80 (g/L) | 0.49 |
| Cholesterol | 5.2 | 5.0 | 4.3–5.6 (mmol/L) | 0.47 |
| Triglycerides | 1.1 | 1.1 | 0.80–2.00 (mmol/L) | 0.94 |
| HDLd | 1.3 | 2.0 | 0.7–1.5 (mmol/L) | 0.22 |
| LDLe | 3.5 | 3.0 | 1.9–4.5 (mmol/L) | 0.05 |
| Iron | 12.5 | 12.8 | 11.0–30.0 (µmol/L) | 0.86 |
| Zinc | 12.7 | 12.4 | 10–18 (µmol/L) | 0.70 |
| Vitamin B1 | 126 | 135 | 74–222 (nmol/L) | 0.27 |
| Vitamin B6 | 61 | 78 | 20–122 (nmol/L) | 0.16 |
| Vitamin B12 | 0.23 | 0.27 | 0.15–0.67 (nmol/L) | 0.18 |
| Folic acid | 13.9 | 17.5 | 7.0–45.4 (mmol/L) | 0.24 |
a t test
bAspartate aminotransferase
cAlanine aminotransferase
dHigh-density lipoprotein
eLow-density lipoprotein
Laboratory measurements after 7 years: VBG versus GB
| VBG “non-converted” ( | RYGB “converted VBG” ( | Normal range |
| |
|---|---|---|---|---|
| Hemoglobin | 7.7 | 7.9 | 7.5–10.0 (mmol/L) | 0.79 |
| ASATb | 18 | 21 | <35 (U/L) | 0.32 |
| ALATc | 20 | 25 | <40 (U/L) | 0.32 |
| Albumin | 41 | 38 | 35–50 (g/L) | 0.13 |
| Total protein | 68 | 66 | 60–80 (g/L) | 0.58 |
| Cholesterol | 4.8 | 4.9 | 4.3–5.6 (mmol/L) | 0.92 |
| Triglycerides | 0.9 | 1.2 | 0.80–2.00 (mmol/L) | 0.31 |
| HDLd | 1.4 | 2.2 | 0.7–1.5 (mmol/L) | 0.32 |
| LDLe | 2.9 | 3.0 | 1.9–4.5 (mmol/L) | 0.95 |
| Iron | 15.0 | 11.6 | 11.0–30.0 (µmol/L) | 0.21 |
| Zinc | 12.9 | 12.2 | 10–18 (µmol/L) | 0.53 |
| Vitamin B1 | 135 | 136 | 74–222 (nmol/L) | 0.93 |
| Vitamin B6 | 91 | 69 | 20–122 (nmol/L) | 0.39 |
| Vitamin B12 | 0.27 | 0.26 | 0.15–0.67 (nmol/L) | 0.85 |
| Folic acid | 17.5 | 16.1 | 7.0–45.4 (mmol/L) | 0.53 |
a t test
bAspartate aminotransferase
cAlanine aminotransferase
dHigh-density lipoprotein
eLow-density lipoprotein